| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | APRIL; CD256; TALL2; ZTNF2; TALL-2; TRDL-1; UNQ383/PRO715 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human TNFSF13 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于TNFSF13(APRIL)抗体的代表性文献摘要：
---
1. **文献名称**：*Targeting TNFSF13 in systemic lupus erythematosus*
**作者**：Stohl W, et al.
**摘要**：研究评估了抗TNFSF13单克隆抗体(如Atacicept)在系统性红斑狼疮(SLE)中的治疗潜力，通过阻断APRIL信号通路减少B细胞异常活化，临床试验显示可降低自身抗体水平并缓解疾病活动度。
---
2. **文献名称**：*APRIL-neutralizing antibody suppresses tumor growth in B-cell malignancy models*
**作者**：Tai YT, et al.
**摘要**：该研究开发了一种人源化抗TNFSF13抗体，证明其能有效抑制APRIL与BCMA/TACI受体的结合，在多种B细胞淋巴瘤和小鼠模型中显著抑制肿瘤增殖并延长生存期。
---
3. **文献名称**：*Dual targeting of BAFF and APRIL in autoimmune disorders*
**作者**：Sakurai D, et al.
**摘要**：比较了单靶向TNFSF13(APRIL)与双靶向BAFF/APRIL抗体的疗效，发现双靶向策略在类风湿性关节炎模型中更有效抑制浆细胞分化及IgG分泌，为联合阻断策略提供理论依据。
---
如需具体文献链接或补充说明，可进一步提供研究方向(如临床/机制)。
**Background of TNFSF13 Antibodies**
TNFSF13 (tumor necrosis factor superfamily member 13), also known as APRIL (A Proliferation-Inducing Ligand), is a cytokine involved in immune regulation, particularly B-cell survival, differentiation, and antibody production. It binds to receptors BCMA (B-cell maturation antigen), TACI (transmembrane activator and calcium modulator), and heparan sulfate proteoglycans, playing roles in autoimmune diseases, lymphoid malignancies, and immunodeficiency disorders.
TNFSF13 antibodies are therapeutic or research tools designed to modulate APRIL-mediated signaling. In autoimmune conditions like systemic lupus erythematosus (SLE) or IgA nephropathy, overactive APRIL signaling drives pathogenic autoantibody production. Neutralizing antibodies (e.g., anti-APRIL monoclonal antibodies) block TNFSF13-receptor interactions, suppressing B-cell hyperactivity. Conversely, agonist antibodies may enhance APRIL signaling in immunodeficiency contexts.
Therapeutic development focuses on specificity and safety, as APRIL shares receptors with BAFF (another TNF family cytokine). Selective targeting aims to avoid broad immunosuppression. Preclinical and clinical studies explore TNFSF13 antibodies in diseases like multiple myeloma and autoimmune disorders, with some candidates in Phase II trials. Challenges include balancing efficacy with infection risks and optimizing receptor selectivity. Overall, TNFSF13 antibodies represent a promising avenue for immune modulation, though further research is needed to refine their clinical applications.
(Word count: 198)
×
